Intricacies of Childhood Cancer Required Specialized Approach
News Mar 01, 2018 | Original Story from St. Jude Children’s Research Hospital
By Dr Erhabor Osaro (Own work) [CC BY-SA 3.0 (https://creativecommons.org/licenses/by-sa/3.0)], via Wikimedia Commons
Researchers have determined that children and adults with cancer usually have different mutated genes driving their disease, which suggests they would likely benefit from different therapies. The finding, from a collaborative study led by St. Jude Children’s Research Hospital, underscores the need to develop precision medicines for pediatric cancer.
The research, along with a companion study led by scientists at the Hopp Children’s Cancer Center at NCT Heidelberg (KiTZ) and the German Cancer Research Center, Heidelberg, appears as an advance online publication today in the scientific journal Nature.
The findings from the back-to-back papers provide the most comprehensive analysis yet of the genomic landscape of childhood cancer across multiple subtypes. The results will help guide clinical and laboratory research to improve understanding, diagnosis and treatment of pediatric cancer patients worldwide, including the estimated 15,780 children and adolescents diagnosed annually in the U.S.
Rather than focusing on a single tumor type, the St. Jude—led study evaluated data generated by members of the Therapeutic Applicable Research to Generate Effective Treatments (TARGET) program. The study was funded in part by the National Cancer Institute of the National Institutes of Health.
The scientists evaluated six cancer subtypes using three different, next-generation sequencing approaches. The researchers compared somatic genetic mutations—genomic changes found in cancer cells but not in normal cells—and their impact on key biological processes in tumor and normal tissues of 1,699 pediatric cancer patients. The approach, called pan-cancer analysis, revealed that only 45 percent of the mutated genes “driving” cancer in children are the same as the genes “driving” cancer in adults.
“This shows for the first time that pediatric and adult cancers frequently arise from different genes with different mutations,” said corresponding author Jinghui Zhang, Ph.D., chair of the St. Jude Department of Computational Biology. The first authors are Xiaotu Ma, Ph.D., and Yu Liu, Ph.D., both members of her laboratory.
“The results really bring home the message that pediatric cancer patients are not small adults and their disease should not be treated as if that were the case,” Zhang said. “Better treatments and more sensitive diagnostic tests require understanding the biology driving pediatric cancer. These results provide a better roadmap for researchers working in the laboratory and the clinic.”
Treatment advances have pushed cure rates for pediatric cancer to better than 80 percent, but cancer remains the leading cause of death by disease in U.S. children ages 1 to 19. Treatments often involve major life-long side effects, including the risk of second cancers.
The Genomic Architecture of Pediatric Cancers
The analysis included patients enrolled in the clinical trials of the Children’s Oncology Group, a clinical research cooperative. The patients had acute lymphoblastic leukemia, both B and T-cell ALL; acute myeloid leukemia; the bone cancer osteosarcoma; the kidney cancer called Wilms tumor; and neuroblastoma, a tumor of the sympathetic nervous system.
Unlike a previously published adult pan-cancer analysis, which focused primarily on coding sequence mutations, the St. Jude team analyzed variations in DNA copies and chromosomal rearrangements. The data were from whole genome sequencing of the complete DNA of patients’ tumor and normal tissue. Transcriptome sequencing was also performed. That provided a snapshot of gene expression in cells. The analysis also included the first comprehensive evaluation of quantitative and qualitative expression of mutant versus wild-type alleles in multiple cancer subtypes.
The sequencing data was provided by the National Cancer Institute’s TARGET initiative. TARGET was launched to understand the genetic changes that underlie pediatric cancer. The intention of the program was to use the data by the research community to improve the precision oncology treatment of pediatric cancers.
For this study, Zhang and her colleagues processed the sequencing data using a uniform analytic framework. “Looking across tumor types helps to identify really important mutations in pediatric cancer and understand the pathways involved,” she said.
Genomic Alterations Revealed
For example, the analysis identified unexpected patterns of mutations, or mutational signatures, in eight of the 689 patients with B-ALL. The patients’ DNA had a mutational signature consistent with exposure to ultraviolet light, which was previously observed exclusively in skin cancers. The patients also shared another genomic abnormality—too many or too few chromosomes. “This finding suggests that exposure to ultraviolet light may be a previously unrecognized environmental factor that increases the risk for developing leukemia in some children,” said co-author Ludmil Alexandrov, Ph.D., of the University of California, San Diego.
In addition, the analysis revealed that rather than point mutations in DNA, a majority (62 percent) of the mutations driving pediatric cancer were copy-number alterations and structural variations. Copy-number alterations leave patients with too many or too few copies of particular genes. Structural variations involve gene rearrangements. “This shows that as genomics moves into the clinic, diagnostic testing for pediatric patients must include copy-number changes and structural variations,” Zhang said.
Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT BiotechNews
Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.READ MORE
SCRaMbLE Speeds Up Yeast EvolutionNews
Scientists have created a new way of speeding up the genome evolution of baker’s yeast Saccharomyces cerevisiae. This is to develop a synthetic yeast strain that can be transformed on demand, making it industrial applications such as the mass production of advanced medicines to treat illnesses such as malaria and tuberculosis (TB).READ MORE
Artificial Cellular Compartments BuiltNews
How to install new capabilities in cells without interfering with their metabolic processes? A team from the Technical University of Munich (TUM) and the Helmholtz Zentrum München have altered mammalian cells in such a way that they formed artificial compartments in which sequestered reactions could take place, allowing the detection of cells deep in the tissue and also their manipulation with magnetic fields.READ MORE